- | Colorectal cancer[33] | Unknown | A 87-drug panel | Completed | This trial enrolled 28 patients and successfully established 19 organoids, out of which 15 were utilized for drug screening. One patient underwent treatment based on the drug sensitivity results of the organoid and showed partial remission after 3 months of evaluation |
2014-003811-13 | Colorectal cancer[34] | 2014 | Palbociclib, axitinib, selumetinib, gefitinib | Completed | This trial enrolled 54 patients and successfully established 31 organoids, of which 25 were utilized for drug screening. Out of the 25 organoids, 19 received drug sensitivity results. Based on these results, 6 patients underwent treatment; however, none of them showed any efficacy |
NCT05842187 | Pancreatic cancer/gastric cancer | 2023 | Various clinically approved drugs | Recruiting | This trial will use organoid models to guide the precision treatment of metastatic pancreatic cancer and gastric cancer |
NCT04931394 | Pancreatic cancer | 2021 | Gemcitabine, 5-fluorouracil, paclitaxel, oxaliplatin, irinotecan | Recruiting | This trial will use organoid models to guide the adjuvant chemotherapy of pancreatic cancer |
NCT04931381 | Pancreatic cancer | 2021 | Gemcitabine, 5-fluorouracil, paclitaxel, oxaliplatin, irinotecan | Recruiting | This trial will use organoid models to guide the chemotherapy of advanced pancreatic cancer |
NCT06102824 | Breast cancer | 2023 | Taxane, anthracycline, 5-fluorouracil, gemcitabine, vinorelbine, eribulin, utidelone, carboplatin, sacituzumab govitecan, and trastuzumab deruxtecan | Recruiting | This trial will use organoid models to guide the treatment of advanced breast cancer |
NCT06268652 | Breast cancer | 2024 | Personalized drug library contains 55 drugs approved by the FDA | Recruiting | This trial will compare the efficacy of organoid-guided personalized treatment with the treatment of physician’s choice in breast cancer |
NCT05832398 | Colorectal cancer | 2023 | Oxaliplatin, irinotecan, 5-fluorouracil | Recruiting | This trial will use organoid models to guide the precise chemotherapy of colorectal cancer |
NCT05177432 | Breast cancer | 2021 | 10-12 anti-cancer drugs | Recruiting | This trial will use organoid models to develop a quadratic phenotypic optimization platform (QPOP) to guide the treatment of breast cancer |
NCT05669586 | Lung cancer | 2023 | Unknown | Recruiting | This trial will use organoid models to guide the precise treatment of refractory non-small cell lung cancer |
NCT05813509 | Ovarian cancer | 2022 | 10 potential clinical therapeutic drugs | Recruiting | This trial will use organoid models to guide the personalized treatment of ovarian cancer |
NCT06246630 | Pancreatic neuroendocrine tumor | 2024 | Various clinically approved drugs | Not yet recruiting | This trial will use organoid models to guide the treatment of pancreatic neuroendocrine tumors |
NCT05024734 | Bladder cancer | 2022 | Epirubicin, mitomycin, gemcitabine, docetaxel | Recruiting | This trial will use organoid models to guide the treatment of non-muscle invasive bladder cancers |
NCT06077591 | Solid tumors | 2024 | Unknown | Not yet recruiting | This trial will use organoid models and next-generating sequencing to guide the treatment of advanced and inoperable solid tumors |
NCT05352165 | Colorectal cancer | 2023 | Oxaliplatin, irinotecan, 5-fluorouracil | Not yet recruiting | This trial will compare the efficacy of organoid-guided neoadjuvant chemotherapy with traditional neoadjuvant chemotherapy regimens in advanced colorectal cancer |
NCT05378048 | Abdominal tumors | 2022 | Unknown | Withdrawn | This trial will compare the efficacy of organoid-guided personalized treatment with traditional treatment strategies in advanced and inoperable abdominal tumors |
NCT04279509 | Solid tumors | 2019 | 5-fluorouracil, carboplatin, cyclophosphamide, docetaxel, doxorubicin, gemcitabine, irinotecan, oxaliplatin, paclitaxel, vinorelbine, etoposide, ifosfamide, methotrexate, pemetrexed and topotecan | Unknown | This trial will use organoid models to conduct high-throughput drug screening to guide the chemotherapy of refractory solid tumors |
NCT05267912 | Any cancer type | 2022 | A panel of drugs (chemotherapy, hormonal therapy, targeted therapy) | Recruiting | This trial is a multi-center study evaluating the feasibility of using organoid models to guide the precision treatment of multiple advanced tumors |
NCT04450706 | Breast cancer | 2021 | Unknown | Recruiting | This trial will use organoid models to guide the precision treatment of metastatic breast cancers |
NCT06057298 | Colorectal cancer | 2021 | Oxaliplatin, mitomycin | Recruiting | This trial will use organoid models to guide the hyperthermic introperitoneal chemotherapy of colorectal cancers with peritoneal metastasis |
NCT04842006 | Colorectal cancer | 2021 | Capecitabine, oxaliplatin | Recruiting | This trial will use organoid models to guide the neoadjuvant and adjuvant therapy of colorectal cancer |
NCT05725200 | Colorectal cancer | 2022 | Alectinib, cetuximab, crizotinib, dasatinib, everolimus, encorafenib, gemcitabine, idelalisib, larotrectinib, methotrexate, palbociclib, panobinostat, pembrolizumab, petrozumab, trastuzumab, talazoparib, venetoclax | Recruiting | This trial will use organoid models to guide the precision treatment of metastatic colorectal cancer |
NCT05464082 | Breast cancer | 2023 | Unknown | Recruiting | This trial will use organoid models to guide the precision treatment of metastatic triple-negative breast cancers |
NCT03778814 | Lung cancer/solid tumors | 2018 | Engineering TCR-T cells | Recruiting | This trial will use organoid models to guide the TCR-T immunotherapy of lung cancers and other solid tumors |
NCT05429684 | Breast cancer | 2021 | Trastuzumab, pertuzumab, nab paclitaxel, pyrotinib, capecitabine, T-DM1, everolimus, CDK4/6 inhibitor, aromatase-Inhibitors, anti-PD-1 monoclonal antibody | Recruiting | This trial will use organoid models to guide the precision treatment of refractory HER2-positive breast cancers |
NCT05381038 | Solid tumors | 2022 | Azacitidine, docetaxel, paclitaxel, irinotecan | Not yet recruiting | This trial will use organoid models to develop a QPOP and CURATE.AI, which will guide the personalized combinatory therapy with azacytidine in solid tumors. |
NCT06227065 | Bladder cancer | 2024 | Epirubicin, mitomycin, gemcitabine, docetaxel | Not yet recruiting | This trial will use organoid models to guide the precise neoadjuvant chemotherapy of low-grade non-muscle invasive bladder cancers |
NCT05432518 | Glioblastoma | 2023 | Afatinib, dasatinib, palbociclib, everolimus, olaparib | Recruiting | This trial will use organoid models to guide the treatment of refractory glioblastoma |
NCT05473923 | Glioma | 2022 | Unknown | Recruiting | This trial will use organoid models to guide the precision treatment of refractory high-grade glioma |
NCT05532397 | Astrocytoma | 2023 | Unknown | Recruiting | This trial will use organoid models to guide the combinatory therapy of refractory high-grade astrocytoma |
2020-003395-41 | Colorectal cancer | 2020 | Alectinib, crizotinib, dasatinib, everolimus, gemcitabine, idelalisib, larotrectinib, methotrexate, palbociclib, panobinostat, pembrolizumab, pertuzumab, trastuzumab, talazoparib, venetoclax, cetuximab, encorafinib | Recruiting | This trial will use organoid models to guide the personalized therapy of colorectal cancers |